Floatz logo

20 assets in Prostate Small Cell Carcinoma

Therapeutic assets addressing Prostate Small Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Carboplatin
Prostate Small Cell Carcinoma
M.D. Anderson Cancer CenterP2BB (67)
Cabazitaxel
Prostate Small Cell Carcinoma
M.D. Anderson Cancer CenterP2B (60)
Pembrolizumab
Prostate Small Cell Carcinoma
Rahul AggarwalP2B (60)
Prednisone
Prostate Small Cell Carcinoma
Fred Hutchinson Cancer CenterP2B (60)
Apalutamide
Prostate Small Cell Carcinoma
Rahul AggarwalP2CCC (53)
Bet Bromodomain Inhibitor Zen-3694
Prostate Small Cell Carcinoma
Rahul AggarwalP2CCC (53)
Cabozantinib
Prostate Small Cell Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Cetrelimab
Prostate Small Cell Carcinoma
Rahul AggarwalP2CCC (53)
Enzalutamide
Prostate Small Cell Carcinoma
Rahul AggarwalP2CCC (53)
Ipilimumab
Prostate Small Cell Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Niraparib
Prostate Small Cell Carcinoma
M.D. Anderson Cancer CenterP2CCC (53)
Nivolumab
Prostate Small Cell Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Oxodotreotide
Prostate Small Cell Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Bendamustine
Prostate Small Cell Carcinoma
Fred Hutchinson Cancer CenterP1CC (43)
Cis-Diamminedichloroplatinum Ii
Prostate Small Cell Carcinoma
Jonsson Comprehensive Cancer CenterP1CC (43)
Cyclophosphamide
Prostate Small Cell Carcinoma
Fred Hutchinson Cancer CenterP1CC (43)
Docetaxel
Prostate Small Cell Carcinoma
Jonsson Comprehensive Cancer CenterP1CC (43)
Etoposide
Prostate Small Cell Carcinoma
Jonsson Comprehensive Cancer CenterP1CC (43)
Fludarabine
Prostate Small Cell Carcinoma
Fred Hutchinson Cancer CenterP1CC (43)
T-Cell Receptor-Engineered T-Cells
Prostate Small Cell Carcinoma
Fred Hutchinson Cancer CenterP1CC (40)